
Biologics outsourcing includes contract development and manufacturing services for biologics such as monoclonal antibodies, recombinant proteins, blood factors, vaccines, among others. Biologics are complex therapeutic proteins produced using advanced recombinant DNA technologies. The growing demand for biologics owing to their higher selectivity and efficacy over small molecule drugs is driving the need for outsourcing biologics development and manufacturing. However, the complex production processes and stringent quality requirements associated with biologics manufacturing demands specialized expertise and large capital investments that most small biotech companies cannot afford in-house. This is a key factor fueling the growth of biologics outsourcing market.
Global Biologics Outsourcing market is estimated to be valued at US$ 19.67 Billion in 2023 and is expected to exhibit a CAGR of 12.9% during the forecast period (2023-2030).
Key Takeaways
Key players: Key players operating in the biologics outsourcing market include Lonza Group, Boehringer Ingelheim, Samsung Biologics, Fujifilm Diosynth Biotechnologies, WuXi Biologics, AbbVie Inc., AGC Biologics.
Key opportunities: Increasing R&D investment of pharmaceutical companies in cell and gene therapies, growing Biologics Outsourcing Market Demand post-patent expiry of biologic drugs, and rising preference for outsourcing non-core activities are expected to create significant opportunities for CDMOs over the forecast period.
Technological advancements: Advancements in recombinant DNA technologies such as modular manufacturing platforms, continuous bioprocessing, single-use technologies are helping CMOs improve production yields, speed, capacity, and flexibility to cater to changing market demands which is fueling service outsourcing.
Market drivers
Higher demand for affordable biologics: The growing incidence of chronic diseases and demand for affordable treatment options is expected to drive the demand for biosimilars and biobetters over the forecast period. This in turn is anticipated to drive increased outsourcing of biologics development and manufacturing to CDMOs.
Focus on core competencies: Pharmaceutical companies are increasingly outsourcing non-core activities like process and product development, clinical and commercial manufacturing to contract service providers in order to focus internal resources on drug discovery and clinical research. This is a major factor driving the biologics outsourcing market.
Current challenges in Biologics Outsourcing Market:
The biologics outsourcing market is facing various challenges which need to be addressed to sustain its growth rate. Some of the key challenges in the market are:
1. High R&D and manufacturing costs: Developing novel biologics requires substantial investments and expertise. Outsourcing reduces costs but maintaining quality and ensuring compliance increases expenses.
2. Stringent regulatory requirements: Biologics are regulated stringently due to safety concerns. Meeting global quality standards during development and production through outsourcing is challenging.
3. Intellectual property and data security: Protecting sensitive knowledge and ensuring data privacy during outsourcing raises legal and ethical compliance issues. Leakage of proprietary information can harm business.
4. Dependence on contract service providers: Reliance on third parties for specialized services increases the risk of delays, cost overruns or inconsistent performance due to supply chain disruptions.
5. Shortage of specialized expertise: Finding qualified CDMOs with experience across diverse technologies like cell and gene therapies is difficult due to the nascent stage of several novel modalities.
SWOT Analysis
Strength: Existing CDMOs have large manufacturing capacities and wide therapeutic expertise. They provide end-to-end services from drug development to commercial production.
Weakness: Lack of in-house capabilities limits control over quality, intellectual property and timelines. Outsourcing key activities increases dependence on external vendors.
Opportunity: Growing demand for affordable biologics and entry of new modalities will drive greater outsourcing of specialized activities. Emerging markets offer lower costs for clinical trials and manufacturing.
Threats: Consolidation among CDMOs reduces choices. Rising costs, regulatory hurdles and import barriers in key emerging countries can impact outsourcing decisions. In terms of value, North America and Europe together account for around 65% share of the global biologics outsourcing market due to concentration of leading drug makers in these regions. However, Asia Pacific region is witnessing the fastest growth owing to expanding biopharma industries, presence of global standards compliant CDMOs and lower costs in countries like China and India.
Get this Report in Japanese Language:
Get this Report in Korean Language:
About Author:
Ravina Pandya Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.
(https://www.linkedin.com/in/ravina-pandya-1a3984191)